Document is current
Any future updates will be listed below
-
Authors
DeMichele, A.
Dueck, A. C.
Hlauschek, D.
Martin, M.
Burstein, H.
Pfeiler, G.
Zdenkowski, N.
Wolff, A.
Bellet-Ezquerra, M.
Winer, E.
Balic, M.
Miller, K.
Colleoni, M.
Lake, D.
Rubovsky, G.
Cameron, D.
Balko, J.
Singer, C. F.
Nowecki, Z.
Iwata, H.
Wolmark, N.
Parraga, K. A.
Rugo, H.
Steger, G. G.
Traina, T.
Werutsky, G.
Czajkowska, D.
Metzger, O.
El-Abed, S.
Theall, K. P.
Lu, R. D.
O’Brien, P.
Fesl, C.
Mayer, E.
Gnant, M.
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct02513394 at ClinicalTrials.govDocuments that mention this clinical trial
Correction: CDK4/6 inhibitors in the treatment of patients with breast cancer: summary of a multidisciplinary round-table discussion
https://doi.org/10.1136/esmoopen-2018-000368corr1
CDK4/6 inhibitors in the treatment of patients with breast cancer: summary of a multidisciplinary round-table discussion
https://doi.org/10.1136/esmoopen-2018-000368
Impact of adding palbociclib on treatment adherence to ongoing adjuvant endocrine treatment in the global randomized PALLAS randomized trial in patients with early breast cancer
https://doi.org/10.1007/s10549-025-07653-2
Impact of BMI in Patients With Early Hormone Receptor–Positive Breast Cancer Receiving Endocrine Therapy With or Without Palbociclib in the PALLAS Trial
https://doi.org/10.1200/jco.23.00126
Outcomes in stage IIA versus stage IIB/III in the PALLAS trial [ABCSG-42/AFT-05/PrE0109/BIG-14-13])
https://doi.org/10.1186/s13058-024-01941-3
Analysis of the sensitivity to endocrine therapy (SET) assay in the PALLAS adjuvant trial of palbociclib in HR+/HER2- breast cancer (ABCSG-42/AFT-05/BIG-14-13).
https://doi.org/10.1200/jco.2024.42.16_suppl.538
-
Funding
Funding for this research was provided by:
Pfizer
- License Information
-
More Information
Article History
Received: 20 June 2024
Accepted: 2 December 2024
First Online: 23 January 2025
Declarations
:
: In the U.S., the study protocol was approved by the institutional review board and the Advarra Protocol Approval number is Pro00034499. Outside the U.S., the trial was approved by respectively responsible institutional review boards and ethics committees. All analyzed patients provided written informed consent, and the trial was performed in strict accordance with ICH GCP guidelines (ClinicalTrials.gov identifier: NCT02513394, EudraCT 2014-005181-30).
: Institutional research grants from Novartis, Pfizer, Genentech, and Neogenomics. The authors declare no competing interests.
